[Risk factors for short-term outcome of patients with HBV-related acute-on-chronic liver failure].
OBJECTIVE
To investigate the risk factors for the short-term outcome of patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF), and to establish a risk model for predicting the short-term outcome of these patients.


METHODS
A total of 338 patients with HBV-related ACLF who were admitted to 30 Lod hospital of PLA hospital from January 2010 to January 2014 were enrolled, and a prospective clinical follow-up was performed for them. Multivariate logistic regression was used to determine the risk factors for short-term (12 weeks) outcome, the predictive model with logistic regression equation was established, and the predictive value of this model was evaluated.


RESULTS
The multivariate logistic regression analysis showed that age, a family history of hepatitis B, hepatic encephalopathy (HE), hepatorenal syndrome (HRS), white blood cell (WBC), platelet (PLT), international normalized ratio (INR), total bilirubin (TBil), total bile acid (TBA), creatinine, Na, HBV DNA, and HBeAg were the independent risk factors for the short-term outcome of these patients. Logistic(p) = -4.466 + 1.192 age + 1.631 family history of hepatitis B + 1.091 HE + 1.631 HRS + 1.208 WBC -1.487 PLT + 1.092 INR + 1.446 TBil + 1.608 TBA -1.101 CHE + 1.279 CRE -1.713 Na + 1.032 HBV DNA + 0.833 HBeAg. The area under the receiver operating characteristic curve of the model for the prediction of short-term outcome was 0.930, the cut-off value was 3.16, the sensitivity was 0.860, and the specificity was 0.871. With the increasing scores of the equation, the mortality of patients tended to increase gradually.


CONCLUSIONS
Age, a family history of hepatitis B, HE, HRS, WBC, PLT, INR, TBil, TBA, CHE, CRE, Na, HBV DNA, and HBeAg are the independent risk factors for the short-term outcome of patients with HBV-related ACLF. The model for predicting short-term outcome established on the basis of independent risk factors has a better clinical value in guiding clinical therapy.
Medical School of PLA, Beijing 100853, China; Department of Liver Failure Treatment and Research Center, 302ed hospital of PLA, Beijing 100039, China.
C
C
Li
Department of Liver Failure Treatment and Research Center, 302ed hospital of PLA, Beijing 100039, China.
S
S
Lyu
Department of Liver Failure Treatment and Research Center, 302ed hospital of PLA, Beijing 100039, China.
B
B
Zhu
Department of Liver Failure Treatment and Research Center, 302ed hospital of PLA, Beijing 100039, China.
Z H
ZH
Wan
Department of Liver Failure Treatment and Research Center, 302ed hospital of PLA, Beijing 100039, China.
W S
WS
Liu
The 61785ed Military Outpatient Department, Beijing 100075, China; Department of Liver Failure Treatment and Research Center, 302ed hospital of PLA, Beijing 100039, China.
L
L
Guo
Department of Liver Failure Treatment and Research Center, 302ed hospital of PLA, Beijing 100039, China.
S L
SL
You
Medical School of PLA, Beijing 100853, China; Department of Liver Failure Treatment and Research Center, 302ed hospital of PLA, Beijing 100039, China.
S J
SJ
Xin
D065290:Acute-On-Chronic Liver Failure / Q000175:diagnosis* / Q000821:virology*; D000328:Adult; D001663:Bilirubin / Q000097:blood; D005260:Female; D006509:Hepatitis B; D006515:Hepatitis B virus; D019694:Hepatitis B, Chronic / Q000175:diagnosis* / Q000503:physiopathology; D006801:Humans; D017093:Liver Failure / Q000473:pathology* / Q000503:physiopathology*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D008962:Models, Theoretical; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D012372:ROC Curve; D012307:Risk Factors; D012680:Sensitivity and Specificity
D001663:Bilirubin